Filing Details
- Accession Number:
- 0001415889-25-002160
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-01-28 16:08:45
- Reporting Period:
- 2025-01-24
- Accepted Time:
- 2025-01-28 16:08:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1802665 | Harmony Biosciences Holdings Inc. | HRMY | Pharmaceutical Preparations (2834) | 822279923 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1821102 | Jeffrey Dierks | C/O Harmony Biosciences Holdings, Inc. 630 W Germantown Pike, Suite 215 Plymouth Meeting PA 19462 | Chief Commercial Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-01-24 | 13,125 | $30.69 | 13,125 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-01-24 | 8,000 | $36.94 | 5,125 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2025-01-24 | 5,125 | $37.87 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2025-01-24 | 2,687 | $0.00 | 2,687 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-01-24 | 1,058 | $38.01 | 1,629 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2025-01-27 | 1,629 | $38.02 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option | Disposition | 2025-01-24 | 13,125 | $0.00 | 13,125 | $30.69 |
| Common Stock | Restricted Stock Units | Disposition | 2025-01-24 | 2,687 | $0.00 | 2,687 | $0.00 |
| Common Stock | Stock Option | Acquisiton | 2025-01-25 | 47,200 | $0.00 | 47,200 | $38.01 |
| Common Stock | Restricted Stock Units | Acquisiton | 2025-01-25 | 13,450 | $0.00 | 13,450 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 39,375 | 2034-01-24 | No | 4 | M | Direct | |
| 8,063 | No | 4 | M | Direct | ||
| 47,200 | 2035-01-25 | No | 4 | A | Direct | |
| 13,450 | No | 4 | A | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.46 to $37.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.485 to $38.00. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.78 to $38.40. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
- This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
- The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
- The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
Billionaire Hedge Funds
